Diabetes Metab J.  2024 May;48(3):385-386. 10.4093/dmj.2024.0210.

Exploring Renal Pyruvate Metabolism as a Therapeutic Avenue for Diabetic Kidney Injury

• Lee J

• KMID: 2555769
• DOI: http://doi.org/10.4093/dmj.2024.0210

Reference

1. Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic. Nephrol Ther. 2016; 12 Suppl 1:S41–8.

2. Kim MJ, Lee H, Chanda D, Thoudam T, Kang HJ, Harris RA, et al. The role of pyruvate metabolism in mitochondrial quality control and inflammation. Mol Cells. 2023; 46:259–67.

3. Gray LR, Tompkins SC, Taylor EB. Regulation of pyruvate metabolism and human disease. Cell Mol Life Sci. 2014; 71:2577–604.

4. Kang HJ, Min BK, Choi WI, Jeon JH, Kim DW, Park S, et al. Pyruvate dehydrogenase kinase 1 and 2 deficiency reduces high-fat diet-induced hypertrophic obesity and inhibits the differentiation of preadipocytes into mature adipocytes. Exp Mol Med. 2021; 53:1390–401.

5. Rahman MH, Bhusal A, Kim JH, Jha MK, Song GJ, Go Y, et al. Astrocytic pyruvate dehydrogenase kinase-2 is involved in hypothalamic inflammation in mouse models of diabetes. Nat Commun. 2020; 11:5906.

6. Thoudam T, Ha CM, Leem J, Chanda D, Park JS, Kim HJ, et al. PDK4 augments ER-mitochondria contact to dampen skeletal muscle insulin signaling during obesity. Diabetes. 2019; 68:571–86.

7. Tao R, Xiong X, Harris RA, White MF, Dong XC. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes. PLoS One. 2013; 8:e71997.

8. Park BY, Jeon JH, Go Y, Ham HJ, Kim JE, Yoo EK, et al. PDK4 deficiency suppresses hepatic glucagon signaling by decreasing cAMP levels. Diabetes. 2018; 67:2054–68.

9. Forteza MJ, Berg M, Edsfeldt A, Sun J, Baumgartner R, Kareinen I, et al. Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk. Cardiovasc Res. 2023; 119:1524–36.

10. Khang AR, Kim DH, Kim MJ, Oh CJ, Jeon JH, Choi SH, et al. Reducing oxidative stress and inflammation by pyruvate dehydrogenase kinase 4 inhibition is important in prevention of renal ischemia-reperfusion injury in diabetic mice. Diabetes Metab J. 2024; 48:405–17.

11. Oh CJ, Ha CM, Choi YK, Park S, Choe MS, Jeoung NH, et al. Pyruvate dehydrogenase kinase 4 deficiency attenuates cisplatin-induced acute kidney injury. Kidney Int. 2017; 91:880–95.

12. Oh CJ, Kim MJ, Lee JM, Kim DH, Kim IY, Park S, et al. Inhibition of pyruvate dehydrogenase kinase 4 ameliorates kidney ischemia-reperfusion injury by reducing succinate accumulation during ischemia and preserving mitochondrial function during reperfusion. Kidney Int. 2023; 104:724–39.

13. Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 2017; 92:1051–7.

14. Xu C, Kasimumali A, Guo X, Lu R, Xie K, Zhu M, et al. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease. Nephrology (Carlton). 2020; 25:230–8.